EXEL vs MDGL
Exelixis, Inc. and Madrigal Pharmaceuticals, Inc., both Healthcare
Exelixis, Inc. is the larger company at $13B against $12B. Over the past year MDGL returned +57% against +50% for EXEL. Ryufin's sector-relative Smart Score puts EXEL ahead, 8/10 against 5/10.
| Figure | EXEL | MDGL |
|---|---|---|
| Last close | $56.07 | $539 |
| Market cap | $13B | $12B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 18.6 | n/a |
| 1-year return | +50% | +57% |
| 5-year return | +225% | +513% |
| Ryufin Smart Scoresector-relative, 1–10 | 8/10 | 5/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Exelixis, Inc.
Revenue of $611M in Q1 2026, net income $210M. Its largest reported line is Product Gross, 87% of the disclosed total.
Madrigal Pharmaceuticals, Inc.
Revenue of $364M in Q2 2026, net income null.
Open these two in the interactive comparison to add more names, change the period or read the correlation.